Farnesyl transferase inhibitors and uses thereof

Patent metadata

Field	Value
Publication number	US-10745370-B2
Application number	US-201716087103-A
Country	US
Kind code	B2
Filing date	Mar 20, 2017
Priority date	Mar 23, 2016
Publication date	Aug 18, 2020
Grant date	Aug 18, 2020

Abstract

Disclosed herein are novel compounds and uses thereof. The present compounds may suppress the activity of farnesyl transferase and thus, may act as modulators of immune cells; therefor, they are useful for the development of a medicament for treating diseases that are associated with or caused by excessive levels of farnesyl transferase or immune response. Also disclosed herein are pharmaceutical compositions containing the present compounds.

First claim

What is claimed is:

1. A method for treating a subject having or suspected of having a disease or a disorder associated with the activation of farnesyl transferase, comprising administering to the subject a therapeutically effective amount of the compound of formula (1),

wherein, R 1 is H or hydroxyl; and R 2 is hydroxyl or methoxy; and
the disease or disorder associated with the activation of farnesyl transferase is skin transplantation rejection.

2. The method of claim 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the compound of formula (1) is administered to the subject in the amount of about 0.08-10.0 mg/Kg.

Assignees

• Chen Yu-Jen
• Mackay Memorial Hospital

Inventors

• Chen Yu-Jen
• Lin Lie-Chwen

Classifications

• C07D311/22 Primary

  with oxygen or sulfur atoms directly attached in position 4 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title